Biotech | April 03, 2022
New data indicate molnupiravir eliminates Covid-19 rapidly
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
_256_384.jpg)
Kiran will be joining RSE's current Fellowship of around 1,700 Fellows who are recognized as being some of the greatest thinkers, researchers and practitioners working in or with Scotland
The expansion makes Exothera one of the largest viral vector facilities in Europe
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Subscribe To Our Newsletter & Stay Updated
